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The term prostatitis denotes a combination of infectious conditions (acute and 
chronic bacterial prostatitis), chronic pelvic pain syndrome (CPPS) and asymptomatic 
inflammation, of which most of them are CPPS. In spite of many years of investiga-
tion, the cause of CPPS remains elusive and can be multifactorial. Different factors 
have been proposed in the etiopathogenesis of CPPS, including viral infection, psy-
chological stress effects, hormonal and neural factor, T-cell recognition of prostatic 
peptides, and possibly autoimmune diseases. However, a universally effective, reliable 
and lasting beneficial treatment of the CP/CPPS remains uncertain. A wide variety of 
treatments have been applied to CPPS patients, including alpha-blockers, antimicro-
bial therapy, nonsteroidal anti-inflammatory medicine, heat therapy and local infil-
tration therapies. Treatment is clinically based on optimal symptomatic relief and pain 
control. Psychological factors can also affect the development of chronic pain and 
treatment outcomes. Psychological distress comes from both persistent pelvic pain 
and worrying about tissue damage or malignancy development. It is important to in-
form patients about the variety of potential therapies and to develop a trusting rela-
tionship with them. Additional studies in the understanding of the etiologies of CP/
CPPS and the establishment of treatment strategies are urgently needed.
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1.  Introduction
The term prostatitis denotes a combination of infectious 
conditions (acute and chronic bacterial prostatitis), 
chronic pelvic pain syndrome (CPPS) and asymptomatic 
inflammation. The classification of prostatitis, as best 
defined by the National Institute of Diabetes and Digestive 
and Kidney Disease of the U.S. National Institutes of 
Health (NIH), includes all these four syndromes. Category 
III chronic prostatitis (CP) or CPPS is typically character-
ized by reported genital or pelvic pain (in or around the 
prostate, penis, rectum, perineum and scrotum), that 
lasts for more than 3 months. Its symptoms are also 
often associated with variable degrees of voiding pain or 
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ejaculation disturbances in the absence of urinary tract 
infection. There are two types of CPPS as categorized by 
the NIH: inflammatory (type IIIa) and non-inflammatory 
(type IIIb) CPPS. The distinction between inflammatory 
and non-inflammatory CPPS is based on the finding of 
white blood cells in the semen, expressed prostatic se-
cretions, or urine after prostatic massage.
Prostatitis syndrome is not an uncommon disorder. 
The prevalence of prostatitis syndromes in the general 
population ranges from 2.2% to 13.8%,1–3 of which most 
of them are CP/CPPS. The frequency of bacterial prosta-
titis only accounts for 5–10%.4 CP/CPPS is a frustrating 
challenge for both physician and patient. Currently, there 
are no gold-standard and widely acceptable diagnostic 
tests or bio markers available for CPPS. The diagnosis of 
CP/CPPS only depends on the presence of classic symp-
toms of chronic pelvic pain and possibly of lower urinary 
tract symptoms on voiding. Serum white blood cell count 
and prostate-specific antigen level are not helpful in the 
diagnosis of CP/CPPS.
The Meares-Stamey four-glass test or two-glass test 
may provide information to rule out bacterial infection. 
The Meares-Stamey four-glass test5 involves the collec-
tion of sequential specimens of urine before and after 
prostatic massage and prostatic fluid during prostatic 
massage. The simpler two-glass test,6 which involves 
the collection of midstream and initial urine samples 
after prostatic massage, has been shown to be well 
correlated with the four-glass test. However, these find-
ings are not helpful in the diagnosis or management of 
CP/CPPS. The symptoms should be validated with the 
standard questionnaire of the National Institutes of 
Health–Chronic Prostatitis Symptom Index (NIH-CPSI), 
especially before treatment is initiated.7 This question-
naire has become the established international standard 
for symptom evaluation of prostatitis. However, despite 
its important role in evaluating the severity of symp-
toms, it has not been proved to be a valuable diagnostic 
tool.
Despite many years of investigation, the cause of 
CPPS remains elusive and can be multifactorial. Different 
factors have been proposed in the etiopathogenesis of 
CP/CPPS, including viral infection,8,9 psychological stress 
effects,10 hormonal and neural factors,11,12 T-cell recog-
nition of prostatic peptides,13 and possibly autoimmune 
diseases.13–16 Psychological stress and panic are com-
mon findings in men with CP/CPPS. There is also grow-
ing evidence that inflammation plays a significant role in 
CP/CPPS. Elevated levels of proinflammatory cytokines, 
such as interleukin (IL)-1β, IL-6, IL-8 and tumor necrosis 
factor (TNF)-α, have been reported to be associated 
with the severity and diagnosis of CP/CPPS.17
Furthermore, a universally effective, reliable and 
lasting beneficial treatment of CP/CPPS remains un-
certain. The aim of the present review is to provide an 
evidence-based evaluation of the current treatments for 
CP/CPPS.
2.  Alpha-Blockers
The original rationale for alpha-blocker treatment was 
based on clinical and urodynamic observations. Some 
patients with CP/CPPS were found to suffer from blad-
der outflow obstruction, and alpha-blockers have been 
proven effective for patients with bladder outflow ob-
struction and voiding dysfunction. The identification of 
alpha receptors in the urinary tract raises the possibility 
that patients with prostatitis symptoms related to dys-
functional voiding might benefit from alpha-blocker 
therapy. Uro dynamic evaluations have also revealed 
an increased maximal urethral closure pressure and a 
diminished urinary Ňow rate in patients with CP/CPPS.18 
In addition to urodynamic parameters, Mehik et al.19 com-
pared chronic nonbacterial prostatitis patients with nor-
mal controls. The intraprostatic tissue pressure was 
found to be higher in the prostatitis patients, reflecting 
an increase in interstitial resistance or poor tissue micro-
circulation. Alpha-blockers might improve such patho-
physiological processes without affecting voiding.
The findings of randomized, placebo-controlled trials 
showed a clinically significant therapeutic effect with 
these alpha-blockers.12,20–22 Nickel et al.22 completed a 
multicenter study comparing CP/CPPS participants who 
received 6 weeks of tamsulosin (0.4 mg/day) or placebo. 
Assessments were performed on days 15 and 45 using 
the NIH-CPSI scores. Tamsulosin was found to be more 
effective than placebo for participants with higher total 
NIH-CPSI scores at baseline, higher pain scores, higher void-
ing scores, and worse quality of life (QoL) scores. Although 
the patients did not benefit significantly after 2 weeks of 
therapy, there was a significant improvement after 6 weeks 
of therapy.
In a randomized controlled trial to test the efficacy of 
alfuzosin, Nickel et al.23 randomized 272 CP/CPPS pa-
tients to alfuzosin 10 mg/day or placebo for 12 weeks. 
Based on NIH-CPSI scores, both study groups were found 
to have a decrease of at least 4 points in their total NIH-
CPSI scores, but there was no significant difference between 
the two study groups. In addition, a global response as-
sessment showed similar response rates at 12 weeks. 
This trial does not support the use of alfuzosin to reduce 
CP/CPPS symptoms in patients who have not received 
prior treatment with an alpha-blocker. In another pro-
spective, randomized, placebo-controlled trial comparing 
alfuzosin 5 mg twice daily with placebo for a longer period 
of 6 months, it was found that at the end of 6 months of 
active therapy, the alfuzosin group had a statistically sig-
nificant decrease in total NIH-CPSI score and pain domain 
score, but not in the voiding or QoL scores. At the 12-
month follow-up (i.e. 6 months after the treatment was 
discontinued), the symptom scores in all domains of the 
NIH-CPSI showed deterioration, as compared with the 
original baseline scores. Treatment with alpha-blockers may 
be effective for reducing symptoms in men with CP/ CPPS, 
especially in those who have not previously been treated 
Management of male CPPS
Vol. 21, 157–162, December 2010 159
with these drugs and who have had symptoms for a 
relatively short time (< 1 year).
3.  Antimicrobial Therapy
One of the pathogenic hypotheses for CP/CPPS is that 
chronic infection with bacteria is difficult to detect and 
cannot be cultured. Therefore, it is reasonable to treat 
CP/CPPS patients with fluoroquinolones if they have not 
previously been exposed to antibiotics. However, the ef-
fectiveness of antimicrobial agents in men with CPPS is 
controversial. Trials comparing levofloxacin (500 mg/day) 
with placebo for 6 weeks showed that treatment with 6 
weeks of levofloxacin in CP/CPPS men had no statistically 
or clinically significant difference from that with placebo 
at the end of treatment (6 weeks) or at follow-up visits 
(12 weeks).24 Based on a decrease of 6 points in NIH-CPSI 
scores compared to placebo, more patients responded 
in the levofloxacin group; the difference was statistically 
significant only at 3 weeks. Another trial comparing with 
ciprofloxacin 500 mg twice daily (196 patients) for 6 
weeks25 revealed no significant benefit from active therapy 
in terms of a reduction in total NIH-CPSI scores.
Nanobacteria are implicated in stone formation in the 
kidney,26 blood vessels27 and prostate.28 Recently, nanobac-
terial infection has been detected from expressed pros-
tatic secretions and urine samples in CP/CPPS patients.28,29 
A non-randomized trial was performed to evaluate the 
effect of anti-nanobacterial therapy (comET), which con-
sisted of 500 mg tetracycline and ethylene- diamine-
tetraacetic acid (EDTA)28 in 16 CP/CPPS patients. Mean 
NIH-CPSI total scores were found to decrease from 25.7 
to 13.7, and a total of 12 patients (80%) had at least 25% 
improvement on NIH-CPSI and 8 (53%) had at least 50% 
improvement. Therapy designed to eliminate nanobac-
teria resulted in significant improvement in CPPS symp-
toms in the majority of men. Whether the effect was due 
to treatment for stone-producing nanobacteria or through 
some other mechanisms remains unclear. Despite a lack of 
strong supporting evidence from clinical trials, antimicro-
bial and anti-inflammatory agents are often considered 
the mainstay of drug therapy for CP/CPPS, especially for 
newly diagnosed, antimicrobial-naïve patients.30
4.  Nonsteroidal Anti-inflammatory Medicine 
and Analgesics
Nonsteroidal anti-inflammatory drugs (NSAIDs) can in-
hibit the cyclooxygenase enzyme, decrease prostaglandin 
production, and decrease local prostate inflammation. 
However, there are very few studies on the use of NSAIDs 
for CP/CPPS patients. A randomized, placebo-controlled 
trial was tested to compare 6 weeks of 25 mg and 50 mg 
rofecoxib in the treatment of CP/CPPS with placebo.31 
For the higher-dose rofecoxib group (50 mg), there was a 
significant difference (25% decrease or 6-point improve-
ment) in total NIH-CPSI scores, pain and QoL (p < 0.005) 
compared with placebo. Generally, nonselective, low-
potency NSAIDs should be used first and are most likely 
to be helpful when the pain has an inflammatory com-
ponent. The opioids have well-established roles in the 
management of chronic pain syndrome or non-malignant 
neuropathic pain. However, the potential therapeutic 
benefit and risk of drug addiction should be carefully 
weighed. The use of opioids should be carefully reserved 
for treatment-refractory CP/CPPS patients.
5. Heat Therapy
Heat therapy has been delivered with interstitial heat 
and microwaves, transrectally or transurethrally, against 
symptoms of benign prostate enlargement. The mechanism 
underlying the efficacy of hyperthermia in treating pros-
tatitis is unclear. One hypothesis proposes that thermo-
therapy accelerates the resolution of the inflammatory 
process, and alters the sensory nerves in the prostatic 
stroma that transmit pain sensations and alpha-adrenergic 
neuron modulation.32,33 Transurethral microwave ther-
motherapy procedures have been reported to achieve 
intraprostatic temperatures of 55–70°C,32 and transure-
thral needle ablation uses radiofrequency to heat in-
traprostate tissue to 90–100°C.34 However, the results 
on heat therapy for the treatment of CP/CPPS patients are 
inconsistent. In a small, uncontrolled trial, a total of 35 
patients completed transurethral microwave thermother-
apy treatment and were followed-up for 12 months.32 
There were significant improvements in NIH-CPSI pain, 
voiding and QoL subscores from the baseline versus 12-
month follow-up. Treatment discomfort and side effects 
were minimal and transient, resolved spontaneously or 
with medication. One uncontrolled trial (32 patients) 
showed that transurethral needle ablation significantly 
decreased Prostate Symptom Severity Index (PSSI) score 
and leukocyte counts in the expressed prostate secretions 
at 3 and 6 months compared with baseline, without major 
complications on sexual dysfunction or retrograde ejac-
ulation.34 However, another randomized, single-blind con-
trolled trial demonstrated that there were no statistically 
significant differences between the treatment and control 
groups in PSSI, International Prostate Symptom Score, QoL 
and pain domains.35 A larger, well-designed, multicenter 
trial is necessary to elucidate the effect of heat therapy.
6.  Local Infiltration Therapy
The characteristic and dominant symptom of CP/CPPS is 
chronic prostatic or pelvic pain. The clinical observations 
suggest that a significant proportion of pain is of pelvic 
musculoskeletal origin.36 Faced with the obscure nature 
of CP/CPPS and the poor response to oral medication, 
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physicians have considered alternative routes of drug 
administration. Local infiltration injections have several 
advantages over oral drugs and surgical therapies: systemic 
pharmacologic effects are rare; there is no permanent 
destruction of tissue; and graded degrees of actions may 
be achieved by varying the dose injected.
Botulinum (BoNT), a potent neurotoxin, has been used 
in the management of prostate enlargement-induced lower 
urinary tract symptoms.37,38 The mechanisms of BoNT 
involve a direct inhibition of motor neurons, an inhibi-
tion of the release of local neuropeptides (acetylcholine 
and norepinephrine) via vesicle-dependent exocytosis, 
alterations within the autonomic nervous system resulting 
in changes in regional perfusion, and an inhibition of affer-
ent neurotransmitter leading to local analgesic properties.39 
In Zermann et al.’s study,40 a transurethral perisphinc-
teric injection of 200 units of BoNT-A in 11 CP/CPPS pa-
tients was followed by 2–4 weeks of follow-up. Basic 
parameters of bladder function (capacity, sensitivity, 
compliance) were normal. The BoNT injection was fol-
lowed by a pelvic floor muscle weakening and a relief of 
prostatic pain and urethral hypersensitivity. A BoNT-related 
decrease in functional urethral length and postvoid re-
sidual volume and an increase in peak urinary flow were 
also observed. Using a capsaicin-induced prostatitis rat 
model, Chuang et al.41 demonstrated that intraprostatic 
pretreatment with BoNT-A can significantly decrease in-
flammatory cell accumulation and cyclooxygenase-2 ex-
pression in the prostate, ventral horn and dorsal horn of the 
L6 spinal cord. These results suggest a therapeutic poten-
tial of BoNT-A for the treatment of nonbacterial prostatitis.
7.  Other Therapies
An important factor for the development of CP may be sex 
hormone. This proposition has been examined in the fol-
lowing studies. Treating rats with estrogen induced prostatic 
inflammation, while co-administration with testoster-
one limited prostatic inflammation.42 In an autoimmune 
prostatitis rat model, inflammation impaired 5α-reductase 
activity and lowered the intraprostatic level of dihydrotes-
tosterone relative to testosterone.11 The 5α-reductase 
inhibitor, finasteride, can inhibit the conversion of testo-
sterone to dihydrotestosterone, thus increasing local testo-
sterone level. Finasteride 5 mg/day improved subjective 
overall assessment and NIH-CPSI scores compared to 
placebo over a 6-month period in 76 men with inflam-
matory CPPS.12 However, the researchers did not recom-
mend finasteride as monotherapy for CP/CPPS, except 
for men who also have benign prostatic hyperplasia. In an-
other trial, finasteride 5 mg/day over 12 months signifi-
cantly improved PSSI score in men with CP/CPPS, but no 
significant reduction in pain scores was achieved.43
Given the lack of proven efficacy of conventional ther-
apies, there are many patients who turn to phytotherapy 
or other alternative treatments. Pentosan polysulfate 
(PPS), a plant-derived mucopolysaccharide similar to 
glycosaminoglycans, can form a protective layer of the 
urinary tract epithelium. PPS has been used in patients 
with interstitial cystitis, another chronic pelvic pain con-
dition that occurs more commonly in women. In a recent 
study, the potassium chloride (KCl) sensitivity test, espe-
cially the KCl voiding test, was shown to be useful in the 
diagnosis of CP/CPPS patients,44 showing that a defect in 
the bladder mucosa glycosaminoglycan layer is a possible 
etiology of CP/CPPS. Nickel et al.45 conducted a 16-week 
double-blind study of 100 CP/CPPS men who were rando-
mized to receive 300 mg PPS or placebo three times daily. 
A significant number of patients receiving PPS experi-
enced a moderate to marked improvement based on clin-
ical global improvement assessment. The improvement in 
NIH-CPSI QoL domain score was notably different between 
the PPS and control groups. Another longer but smaller 
trial evaluated 28 CP/CPPS patients who received 100 mg 
PPS three times daily for 6 months.46 The decreases in fre-
quency (Symptom Frequency Questionnaire), severity 
(PSSI), and total NIH-CPSI scores were significant when 
baseline was compared with 6 months.
The pollen extract cernilton contains defined pollen 
extract fractions: Cernitin T60 (water-soluble fraction) and 
Cernitin GBX (fat-soluble fraction), which have been 
used for the treatment of benign prostatic hyperplasia and 
CP in Europe. Experimental data in nonbacterial prostatitis 
in rats showed that cernilton has both anti-inflammatory 
and antioxidant effects. Recently, a double-blind, pla-
cebo-controlled study was carried out to investigate CP/
CPPS (NIH IIIa) participants randomized to receive pollen 
extract or placebo for 12 weeks.47 The individual pain 
and QoL domains as well as the total NIH-CPSI score were 
significantly improved after 12 weeks of treatment with 
pollen extract compared to placebo.
Other therapies, such as tricyclic antidepressants, 
muscle relaxant agents, biofeedback, prostatic massage, 
low-energy extracorporeal shock wave therapy and neu-
romodulation, have been evaluated in some small un-
controlled studies, which show some improvement in 
NIH-CPSI scores.48–51 However, studies of larger and ran-
domized placebo-controlled trials are warranted before 
any recommendations can be made.
8.  Conclusion
The present review demonstrates that there are currently 
no universally effective treatments available that can pro-
vide significant lasting effects in CP/CPPS patients. There 
is also no evidence to suggest that treatment for inflamma-
tory and non-inflammatory CP/CPPS should be different. 
Chronic pain is considered not only a primary symptom, 
but also the center of treatment focus. Treatment is clini-
cally based on optimal symptomatic relief and pain control. 
Psychological factors can affect the development of chronic 
pain and treatment outcomes. Psychological distress 
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comes from both persistent pelvic pain and worrying 
about tissue damage or malignancy development. It is im-
portant to inform patients about the varieties of potential 
therapies and to develop a trusting relationship with them. 
Additional studies on the etiologies of CP/CPPS and the 
establishment of treatment strategies are urgently needed.
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